CAMBRIDGE, Mass., May 3, 2016 /PRNewswire/ -- Blueprint
Medicines Corporation (NASDAQ: BPMC), a leader in discovering
and developing highly selective kinase medicines for patients with
genomically defined diseases, today announced that it will report
first quarter 2016 financial results on Tuesday, May 10, 2016. Blueprint Medicines'
management team will host a live conference call and audio webcast
at 8:00 a.m. EDT on Tuesday, May 10, 2016 to discuss the financial
results and provide a corporate update.
To access the conference call, please dial 1-855-728-4793
(domestic) or 1-503-343-6666 (international) and refer to
conference ID 92012739. An audio webcast of the call will also be
available in the Investors section of Blueprint Medicines' website
at http://ir.blueprintmedicines.com. The archived webcast will be
available on Blueprint Medicines' website approximately two hours
after the conference call and will be available for 30 days
following the call.
About Blueprint Medicines
Blueprint Medicines is developing a new generation of highly
selective and potent kinase medicines to improve the lives of
patients with genomically defined diseases. The Company's approach
is rooted in a deep understanding of the genetic blueprint of
cancer and other diseases driven by the abnormal activation of
kinases. Blueprint Medicines is advancing three programs in
clinical development for subsets of patients with gastrointestinal
stromal tumors, hepatocellular carcinoma and systemic mastocytosis,
as well as multiple programs in research and preclinical
development. For more information, please visit
www.blueprintmedicines.com.
Logo -
http://photos.prnewswire.com/prnh/20150605/221118LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-report-first-quarter-2016-financial-results-on-tuesday-may-10-2016-300261517.html
SOURCE Blueprint Medicines Corporation